{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T07:34:28Z","timestamp":1764401668928},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.therap.2016.02.033","type":"journal-article","created":{"date-parts":[[2016,4,11]],"date-time":"2016-04-11T18:35:39Z","timestamp":1460399739000},"page":"491-499","source":"Crossref","is-referenced-by-count":9,"title":["\u00c9tude observationnelle sur l\u2019adh\u00e9sion pr\u00e9coce aux traitements hypotonisants anti-glaucomateux"],"prefix":"10.1016","volume":"71","author":[{"given":"Manon","family":"Belhassen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Laforest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Idlir","family":"Licaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9ric","family":"Van Ganse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2016.02.033_bib0140","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/bjo.2005.081224","article-title":"The number of people with glaucoma worldwide in 2010\u00a0and 2020","volume":"90","author":"Quigley","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.therap.2016.02.033_bib0145","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S0181-5512(06)73905-5","article-title":"Prevalence and description of treatment with intraocular pressure-lowering topical medications in continental France","volume":"29","author":"Delcourt","year":"2006","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.therap.2016.02.033_bib0150","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.therap.2016.02.033_bib0155","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ophtha.2004.12.035","article-title":"Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review","volume":"112","author":"Olthoff","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.therap.2016.02.033_bib0160","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1177\/112067210701700407","article-title":"Changes in medical and surgical treatments of glaucoma between 1997\u00a0and 2003\u00a0in France","volume":"17","author":"Kenigsberg","year":"2007","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.therap.2016.02.033_bib0165","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","article-title":"A new taxonomy for describing and defining adherence to medications","volume":"73","author":"Vrijens","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2016.02.033_bib0170","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1345\/aph.1H018","article-title":"Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures","volume":"40","author":"Hess","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.therap.2016.02.033_bib0175","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health J"},{"key":"10.1016\/j.therap.2016.02.033_bib0180","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00061198-200310000-00001","article-title":"Compliance barriers in glaucoma: a systematic classification","volume":"12","author":"Tsai","year":"2003","journal-title":"J Glaucoma"},{"key":"10.1016\/j.therap.2016.02.033_bib0185","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/01.icu.0000156139.05323.26","article-title":"Compliance and persistency in glaucoma follow-up treatment","volume":"16","author":"Schwartz","year":"2005","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.therap.2016.02.033_bib0190","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/pds.1912","article-title":"Pharmacoepidemiological research using French reimbursement databases: yes we can!","volume":"19","author":"Martin-Latry","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2016.02.033_bib0195","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.respe.2010.04.005","article-title":"French national health insurance information system and the permanent beneficiaries sample","volume":"58","author":"Tuppin","year":"2010","journal-title":"Rev Epidemiol Sante Publique"},{"key":"10.1016\/j.therap.2016.02.033_bib0200","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology, ATC Classification ATC\/DDD Index 2014. www.whocc.no\/atc_ddd_index\/ [Consult\u00e9 le 25 avril 2015]."},{"key":"10.1016\/j.therap.2016.02.033_bib0205","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0895-4356(96)00268-5","article-title":"The assessment of refill compliance using pharmacy records: methods, validity, and applications","volume":"50","author":"Steiner","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.therap.2016.02.033_bib0210","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0181-5512(06)73805-0","article-title":"The French glaucoma and ocular hypertension 1-day study","volume":"29","author":"Villain","year":"2006","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.therap.2016.02.033_bib0215","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jfo.2010.02.004","article-title":"Adherence to glaucoma therapy","volume":"33","author":"Renard","year":"2010","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.therap.2016.02.033_bib0220","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2147\/PPA.S23780","article-title":"Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review","volume":"5","author":"Reardon","year":"2011","journal-title":"Patient Prefer Adherence"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.therap.2016.02.033_bib0225","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.survophthal.2008.08.002","article-title":"Adherence and persistence with glaucoma therapy","volume":"53","author":"Schwartz","year":"2008","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.therap.2016.02.033_bib0230","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1442-9071.2006.01196.x","article-title":"Glaucoma prescribing trends in Australia and New Zealand","volume":"34","author":"Carroll","year":"2006","journal-title":"Clin Experiment Ophthalmol"},{"key":"10.1016\/j.therap.2016.02.033_bib0235","first-page":"261","article-title":"Patient persistence with first-line antiglaucomatous monotherapy","volume":"4","author":"Arias","year":"2010","journal-title":"Clin Ophthalmol Auckl NZ"},{"key":"10.1016\/j.therap.2016.02.033_bib0240","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00417-008-0944-y","article-title":"Prevalence and determinants of non-adherence to topical hypotensive treatment in Dutch glaucoma patients","volume":"247","author":"Olthoff","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.therap.2016.02.033_bib0245","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1517\/14656561003601994","article-title":"Monitoring adherence rates in glaucoma patients using the Travatan Dosing Aid. A 6-month study comparing patients on travoprost 0.004% and patients on travoprost 0.004%\/timolol 0.5% fixed combination","volume":"11","author":"Rossi","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.therap.2016.02.033_bib0250","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2105\/AJPH.83.5.711","article-title":"Treatment for glaucoma: adherence by the elderly","volume":"83","author":"Gurwitz","year":"1993","journal-title":"Am J Public Health"},{"key":"10.1016\/j.therap.2016.02.033_bib0255","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1164\/ajrccm.157.6.9712007","article-title":"Adherence with twice-daily dosing of inhaled steroids. Socioeconomic and health-belief differences","volume":"157","author":"Apter","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.therap.2016.02.033_bib0260","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/thx.2007.086041","article-title":"Patient adherence in COPD","volume":"63","author":"Bourbeau","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.therap.2016.02.033_bib0265","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/1472-6963-12-155","article-title":"Comparison of pharmacy-based measures of medication adherence","volume":"12","author":"Vollmer","year":"2012","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.therap.2016.02.033_bib0135","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1016\/j.ophtha.2013.04.027","article-title":"The cost of glaucoma care provided to Medicare beneficiaries from 2002\u00a0to 2009","volume":"120","author":"Quigley","year":"2013","journal-title":"Ophthalmology"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716300105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716300105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T11:54:33Z","timestamp":1554292473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716300105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0040595716300105"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2016.02.033","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]}}}